<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

MIA PaCa-2

Description

MIA PaCa-2 (Pancreatic Cancer CDX Model) 

The MIA PaCa-2 line was derived from a pancreatic ductal adenocarcinoma (PDAC). It carries a KRAS mutation, common in pancreatic cancer. MIA PaCa-2 is widely applied in drug screening and biomarker studies for PDAC. Its aggressive biology and reproducibility make it a staple in pancreatic cancer research. 

Key Features: 

  • Derived from pancreatic ductal adenocarcinoma. 
  • KRAS-mutant pancreatic cancer model. 
  • Aggressive growth phenotype. 
  • Tumorigenic in xenograft settings. 

Applications: 
MIA PaCa-2 supports therapeutic development for pancreatic cancer. Researchers use it to test chemotherapies and targeted therapies. It is applied in resistance and biomarker discovery studies. Its reproducible growth makes it a reliable PDAC research model.

Details
Tumor Type
Pancreatic
Tumor Subtype
Pancreatic Ductal Adenocarcinoma
Organism
Human
Mouse Sex
Female
Mouse Strain
Athymic Nude
Mutated Genes
ARID1A
Mutation: p.Q321Ter
Effect: Stop-Gain
KRAS
Mutation: p.G12C
Effect: Missense Variant
Impact: Likely Pathogenic & Pathogenic & Not Provided & Pathogenic / Likely Pathogenic
TP53
Mutation: p.R248W
Effect: Missense Variant
Impact: Pathogenic / Likely Pathogenic & Pathogenic & Uncertain Significance & Likely Pathogenic
Lumin Data
RNASeq WES
Expression Data
Growth Curve
View on Lumin